Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.

Ben Hargreaves finds that a new line of attack could be the development of more effective non-opioid painkillers, with one potential therapy moving closer to approval. The opioid epidemic in the ...

The hope is that a new generation of non-opioid analgesics will become available to treat both acute and chronic pain and have a reduced risk of addiction. In 2023, more than 100,000 lives were ...

Leaders with Project Opioid, a non-profit established after the opioid epidemic was declared a public health emergency in ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization -- -- Adds novel, high-capacity, local ...

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look ...

Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) tumbled 55% after the company announced topline results from its PROGRESS Phase 2b study, which evaluated pilavapadin in ...

Shares of Lexicon Pharmaceuticals , Inc. (Nasdaq: NASDAQ: LXRX) plummeted 50% following the announcement of topline results from its Phase 2b PROGRESS study, whic ...

The one-size-fits-all approach to pain management should be a thing of the past. But we’re still not there yet.

The Drug Enforcement Administration finds Alabamians threw away more than 3,500 pounds of prescription drugs during Drug Take Back Day. That was in October 2024. But drug prevention advocates believe ...